Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 9;10:186. doi: 10.1038/s41398-020-00878-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a Treatment schedule. Adult mice were subjected to subdiaphragmatic vagotomy (SDV) and then allowed to recovery for 14 days. On day 15, mice were intraperitoneally (i.p.) injected with lipopolysaccharides (LPS, 0.5 mg/kg) or saline (10 ml/kg). On day 16, fresh feces were collected. Locomotion test and forced swimming test (FST) were performed 22 and 24 h after a single injection of saline or LPS. Blood and brain samples (prefrontal cortex) were collected after behavioral tests (b) Locomotion test (LMT). (tow-way ANOVA: LPS: F_1,36 = 0.014, P = 0.907; SDV: F_1,36 = 0.271, P = 0.606; interaction: F_1,36 = 0.000, P = 0.996). c FST (two-way ANOVA: LPS: F_1,36 = 5.666, P = 0.0243; SDV: F_1,36 = 8.126, P = 0.0081; interaction: F_1,36 = 0.617, P = 0.439). d Representative picture of spleen. e Spleen weight (two-way ANOVA: LPS: F_1,36 = 197.7, P < 0.0001; SDV: F_1,36 = 21.84, P < 0.0001; interaction: F_1,36 = 2.756, P = 0.106). f Plasma levels of IL-6. (two-way ANOVA: LPS: F_1,36 = 58.34, P < 0.0001; SDV: F_1,36 = 5.507, P = 0.0253; interaction: F_1,36 = 9.131, P = 0.0049). g Plasma levels of TNF-α (two-way ANOVA: LPS: F_1,36 = 74.43, P < 0.0001; SDV: F_1,36 = 9.243, P = 0.0047; interaction: F_1,36 = 9.850, P = 0.0036). The data represent mean ± S.E.M. (n = 10). *P < 0.05, **P < 0.01, ***P < 0.0001; N.S. not significant. h There was a positive correlation (r = 0.773, P < 0.001) between spleen weight and plasma IL-6. i There was a positive correlation (r = 0.830, P < 0.001) between spleen weight and plasma TNF-α.